Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2

The novel coronavirus pneumonia (COVID-19) pandemic is a great threat to human society and now is still spreading. Although several vaccines have been authorized for emergency use, only one recombinant subunit vaccine has been permitted for widespread use. More subunit vaccines for COVID-19 should b...

Full description

Bibliographic Details
Main Authors:	Yi-Sheng Sun, Jing-Jing Zhou, Han-Ping Zhu, Fang Xu, Wen-Bin Zhao, Hang-Jing Lu, Zhen Wang, Shu-Qing Chen, Ping-Ping Yao, Jian-Min Jiang, Zhan Zhou
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Series:	Viruses
Subjects:	COVID-19 RBD-Fc fusion protein vaccine neutralizing antibody cellular immune response
Online Access:	https://www.mdpi.com/1999-4915/13/10/1936

Similar Items

Tag-Free SARS-CoV-2 Receptor Binding Domain (RBD), but Not C-Terminal Tagged SARS-CoV-2 RBD, Induces a Rapid and Potent Neutralizing Antibody Response
by: Ting-Wei Lin, et al.
Published: (2022-10-01)

Recombinant expression of SARS-CoV-2 Receptor Binding Domain (RBD) in Escherichia coli and its immunogenicity in mice
by: zahra Rahbar, et al.
Published: (2022-09-01)

Development of an RBD-Fc fusion vaccine for COVID-19
by: Yisheng Sun, et al.
Published: (2024-01-01)

The impact of N-glycans on the immune response of plant-produced SARS-CoV-2 RBD-Fc proteins
by: Theerakarn Srisangsung, et al.
Published: (2024-09-01)

Development of a two-component recombinant vaccine for COVID-19
by: Yi-Sheng Sun, et al.
Published: (2024-12-01)

Application and Validation of SARS-CoV-2 RBD Neutralizing ELISA Assay
by: Z. S Mousa, et al.
Published: (2022-02-01)

Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes
by: Seyed Mostafa Mostafavi Zadeh, et al.
Published: (2024-02-01)

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
by: Federico Bertoglio, et al.
Published: (2021-07-01)

Structural insight into broadening SARS-CoV-2 neutralization by an antibody cocktail harbouring both NTD and RBD potent antibodies
by: Wenling Jiang, et al.
Published: (2024-12-01)

An RBD-Based Diagnostic Method Useful for the Surveillance of Protective Immunity against SARS-CoV-2 in the Population
by: Dolores Adriana Ayón-Núñez, et al.
Published: (2022-07-01)

Inducing enhanced neutralizing antibodies against broad SARS-CoV-2 variants through glycan-shielding multiple non-neutralizing epitopes of RBD
by: Qingyun Zhang, et al.
Published: (2023-12-01)

Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants
by: Chunyan Yi, et al.
Published: (2021-10-01)

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2
by: Jiajia Xie, et al.
Published: (2021-08-01)

Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
by: Amir Ghaemi, et al.
Published: (2022-09-01)

Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model
by: Mohamed A. Wahba, et al.
Published: (2023-02-01)

Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
by: Cong Liu, et al.
Published: (2022-05-01)

Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice
by: Shuo Song, et al.
Published: (2022-01-01)

Antibodies and Vaccines Target RBD of SARS-CoV-2
by: Long Min, et al.
Published: (2021-04-01)

Ginseng Polysaccharide Enhances the Humoral and Cellular Immune Responses to SARS-CoV-2 RBD Protein Subunit Vaccines
by: Jing Zhang, et al.
Published: (2023-12-01)

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
by: Qizhong Lu, et al.
Published: (2021-01-01)

Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection
by: Arunasingam Abayasingam, et al.
Published: (2021-04-01)

Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5
by: Zhantong Wang, et al.
Published: (2023-12-01)

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
by: Ashlesha Deshpande, et al.
Published: (2021-06-01)

Longer Intervals before Vaccination Increase Spike Antibody Titers in Individuals Previously Infected with SARS-CoV-2
by: Xiuqiong Bi, et al.
Published: (2022-04-01)

Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent
by: Yuanyuan Hu, et al.
Published: (2024-03-01)

A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
by: Ling Niu, et al.
Published: (2021-04-01)

Enhanced Immunogenicity and Protective Effects against SARS-CoV-2 Following Immunization with a Recombinant RBD-IgG Chimeric Protein
by: Mariângela de Oliveira Silva, et al.
Published: (2024-03-01)

SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
by: Zheng Liu, et al.
Published: (2022-10-01)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Matthew J. Gorman, et al.
Published: (2021-09-01)

Quality by design for transient RBD-Fc fusion protein production in Chinese hamster ovary cells
by: Araya Jivapetthai, et al.
Published: (2025-03-01)

Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen
by: Min Jiang, et al.
Published: (2021-09-01)

Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2
by: Igor V. Krasilnikov, et al.
Published: (2022-01-01)

Antibodies to NCP, RBD and S2 SARS-CoV-2 in Vaccinated and Unvaccinated Healthcare Workers
by: Agata Błaszczuk, et al.
Published: (2022-07-01)

Tracking Immunity: An Increased Number of COVID-19 Boosters Increases the Longevity of Anti-RBD and Anti-RBD-Neutralizing Antibodies
by: Ching-Wen Hou, et al.
Published: (2025-01-01)

Utilization of Recombinant Baculovirus Expression System to Produce the RBD Domain of SARS-CoV-2 Spike Protein
by: Youpeng Fan, et al.
Published: (2022-06-01)

Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor
by: Sonia Aparecida Andrade, et al.
Published: (2022-07-01)

Foldon fusion of RBD and S1 fragments of SARS‐CoV‐2 to stabilize the structure of subunit protein as a vaccine candidate
by: Gracia Christine Lembong Purwanto, et al.
Published: (2023-09-01)

Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models
by: Alan L. Schmaljohn, et al.
Published: (2019-07-01)

Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice
by: Jian-Piao Cai, et al.
Published: (2023-03-01)

Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants
by: Tasnim Saifudin Zakir, et al.
Published: (2022-01-01)